IP Library › Granted Patent US 7,255,855
Granted Patent B2
US 7,255,855 · App. 10/789,164 · Granted Aug 14, 2007

Surface expression method of peptides P5 and Anal3 using the gene encoding poly-gamma-glutamate synthetase

Assignee: Bioleaders Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,255,855
App. No.
10/789,164
Granted
Aug 14, 2007
Kind
B2
Abstract

The present invention relates to a method for expressing each of peptide antibiotics P5 3 and Ana13 35 having amphiphilicity and showing antibacterial, antifungal and anticancer activities 61, 63, 65, 67, 69, 71, on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from Bacillus sp. strains and involved in the synthesis of poly-gamma-glutamate. Moreover, the present invention relates to lactic acid-forming bacteria having each of the peptide antibiotics P5 15 and Ana13 43 expressed on their surface, and the use thereof. According to the present invention, the peptide antibiotics can be expressed on the surface of various microorganisms transformed with the surface expression vectors. The inventive method for the surface expression of the peptide antibiotics allows the peptide antibiotics to be mass-produced without a purification process. Thus, the inventive method has very high industrial applicability. Further, the present invention can be applied to other peptide antibiotics besides P5 3 and Ana13 35.

Claims (11)

1. A vector for the surface expression of antibiotics, which comprises:

one or more than two genes selected from the group consisting of pgsB, pgsC and pgsA, said genes encoding a poly-gamma-glutamate synthetase complex; and

a gene encoding P5 peptide having antibacterial, antifungal and anticancer activities fused with said gene encoding a poly-gamma-glutamate synthetase complex, wherein P5 peptide is encoded by the base sequence of SEQ ID NO: 4.

2. The vector according to claim 1 , wherein said pgsB, pgsC and pgsA genes have the base sequences described in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.

3. The vector according to claim 1 , wherein the vector contains the pgsA gene among the genes encoding the poly-gamma-glutamate synthetase complex.

4. The vector according to claim 1 , said vector is pHCE1LB:pgsA-P5 for the surface expression of antibiotics, which expresses said antibiotic on the surface of gram-negative and gram positive bacteria.

5. A microorganism transformed with the vector of claim 1 .

6. E. Coli (KCTC 10350BP) transformed with the vector pHCE1LB:pgsA-P5 of claim 4 .

7. A lactic acid-forming bacteria transformed with the vector of claim 1 .

8. A pharmaceutical composition and suspension of the same for antibacterial, antifungal or anticancer application, which comprises, as an active ingredient, the lactic acid-forming bacteria according to claim 7 and having the peptide antibiotic P5 expressed on their surface.

9. The pharmaceutical composition according to claim 8 , wherein said active ingredient is heat-treated.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2004
From: SUNG, MOON-HEE; HONG, SEUNG-PYO; LEE, JONG-SU; JUNG, CHANG-MIN; HAHM, KYUNG-SOO; LEE, DONG-GUN; PARK, YOON KYUNG; KIM, CHUL-JOONG; POO, HA-RYOUNG
To: BIOLEADERS CORPORATION; KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY; CHOSUN UNIVERSITY
Reel/Frame 015038/0833 →
Continuity (1)
Related Publication 20050191720A1 · Sep 1, 2005